ADAMTS9 and neoplasm: ADAMTS9-AS2 acts as a tumor suppressor to inhibit the progression of ccRCC as well as gastric, esophageal, and bladder cancer [38–41]; and SPINT1-AS1 and ATP1A1-AS1 were predicted favorable prognosis in ccRCC [42,43].